It is noteworthy to highlight that the FGFR2::IQCG fusion was identified in tumors from both the initial and sixth relapses, suggesting its potential as a sustained driver of tumor progression, although the unavailability of pre-therapeutic molecular study precludes interpreting whether it played any role in primary chemoresistance. Here, FGFR2 is linked to neoplasm.